Click here to create your personal news page. The news that appears on Applied NeuroSolutions will appear there and be constantly updated. You can then modify the page, share it with your friends, or export it and have it appear elsewhere.

You can also create a personal news page and follow the news that interests you by clicking on the tab labelled 'New page'.  

topics : related - allExplore

Wikio Shopping (beta)

  1. 1. Computers
  2. 2. Electronics
  3. 3. Communication
  4. 4. Household Appliances
  5. 5. Car/Motor Bike
  6. 6. Digital Camera
  7. 7. Mobile Phone
  8. 8. Smartphone
  9. 9. PDA
  10. 10. GPS
  11. 11. LCD Monitor
  12. 12. Printer

New products

  1. 1. Acer X263Wbid
  2. 2. Gigabyte Gigabyte GV-R487-512H-B
  3. 3. Gigabyte M912V
  4. 4. Linksys WRT110
  5. 5. Lian Li EX-H33
  6. 6. ATI Radeon HD 4870 512 MB
  7. 7. Pioneer DVR-LX61D
  8. go to Shopping

Participate

News Categories



Applied NeuroSolutions


Sort by : relevance - date
+Vote!

Applied NeuroSolutions Achieves Q2 2008 Alzheimer's Disease Serum Diagnostic Development Program Milestone

Medical News Today (Free subscription) | 07/03/2008

Applied NeuroSolutions, Inc. (OTC BB:APNS), a biotechnology Company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced the achievement of a key milestone directed to a multi-product program to develop serum-based diagnostic tests for Alzheimer's disease.

+Vote!
+Vote!
+Vote!

Applied NeuroSolutions Q1 2008 Alzheimer's Disease Diagnostic Development Programs Update

Business Wire (Free subscription) | 05/20/2008

VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTCBB:APNS) (www.AppliedNeuroSolutions.com), a

+Vote!

Applied NeuroSolutions To Offer P-Tau 231 Test For Use In Alzheimer's Disease Clinical Trials

Medical News Today (Free subscription) | 05/16/2008

Applied NeuroSolutions, Inc. (OTC BB:APNS)( http://www.AppliedNeuroSolutions.com), a company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials.